Sponsored by The Akkermansia Company
Metabolic diseases such as obesity and type-II diabetes (T2D) affect a significant number of American adults. Its prevalence over this past two decades has continued to increase, making metabolic health an important public health concern. Accumulating evidence suggests that the loss of gut barrier integrity is closely associated with the onset of metabolic disorders, including obesity and type-II diabetes (T2D). Studies have also demonstrated a difference in the intestinal permeability between individuals with or without T2D, reiterating the contribution of intestinal permeability to metabolic disorders.
Not surprisingly, scientists and clinicians are focusing on approaches to help strengthen gut barrier function as a means to mitigate the "leaky gut" and downstream effects on metabolic health outcomes. In this regard, Akkermansia muciniphila, a commensal bacterium that colonizes in the intestinal tract early in life, and which accounts for approximately 3-5% of the total intestinal microbiota in healthy adults, has garnered significant attention since its discovery in 2004. Akkermansia muciniphila resides in the intestinal mucus layer utilizing the mucin as the sole source of carbon, nitrogen, and energy and there is a significant body of mechanistic evidence demonstrating how Akkermansia muciniphila uses specific cell surface proteins as signaling molecules to support gut barrier integrity and potentially GLP-1 levels.
This session will feature the scientist that discovered Akkermansia muciniphila who will present the data generated to date to support a role for a specific Akkermansia muciniphila strain, Akkermansia muciniphila MucT on prevalent metabolic health outcomes including insulinemia and weight management after weight loss. Functional differences between the live and pasteurized versions of Akkermansia muciniphila will also be highlighted. Additionally we will have a clinician's perspective on the use of Akkermansia muciniphila MucT as part of an integrative approach to help patients manage metabolic health issues.
Learning Objectives:
1. Describe the role of Akkermansia muciniphila for gut barrier integrity and metabolic health
2. Review the recent clinical and mechanistic evidence for the metabolic health benefits specific to the Akkermansia muciniphila MucT strain.
3. Describe the differences between live and pasteurized Akkermansia muciniphila
4. Understand how the science on Akkermansia muciniphila MucT translates to everyday clinical practice through case studies
Privacy Policy
He has supervised 120+ PhDs, published 850+ papers, holds 50+ patents, and is the most cited author in Microbiology, Bacterial Genetics, and Microbial Ecology (h-index >200, 200k+ citations).
Dr. De Vos is a member of prestigious academies, including the European Academy of Microbiology, and has received numerous awards such as the Finland Distinguished/Academy Professor titles and a Royal Knighthood in the Order of the Netherlands Lion.
His research focuses on microbes, especially the human gut microbiota, and their role in health and disease. He and his lab discovered Akkermansia muciniphila and further progressed the preclinical and clinical science to find ways to have a sustainable and functional Akkermansia muciniphila strain, known as the MucT strain, and which he is going to talk about today.
